NCT00153907View on ClinicalTrials.gov

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Breast Cancer
Interventions
DRUG

Navelbine

Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.

DRUG

Capecitabine

Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00153907 - Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter